Sonlicromanol ( DrugBank: Sonlicromanol )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
21ミトコンドリア病2

21. ミトコンドリア病


臨床試験数 : 39 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04846036
(ClinicalTrials.gov)
February 1, 20215/2/2021The KHENERGYC StudyA Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial DiseaseMitochondrial Diseases;Mitochondrial DNA tRNALeu(UUR) m.3243ADrug: Sonlicromanol;Drug: PlaceboKhondrion BVJulius Clinical;ProPharma Group;Europees Fonds voor Regionale Ontwikkeling (EFRO);Ardena;CertaraRecruiting0 Years17 YearsAll24Phase 2Netherlands
2EUCTR2020-003124-16-NL
(EUCTR)
12/01/202120/10/2020The KHENERGYC study: a placebo controlled, double-blind study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with a mitochondrial disease.A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease. Genetically confirmed mitochondrial disease;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Product Name: Sonlicromanol
Product Code: KH176
INN or Proposed INN: sonlicromanol
Other descriptive name: KH176
Khondrion B.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
24Phase 2Netherlands